Evidence map›Paper›PMID 34597472›Full record

ArticleBJU international2022

Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.

Dimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Vadim S Koshkin, Joseph J Park, Ajjai Alva, Mehmet A Bilen and 37 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors at 20 institutions in 7 countries.

Dimitrios MakrakisDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0003-3258-2984
Rafee TalukderDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Leonidas N DiamantopoulosDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Lucia Carril-AjuriaDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Daniel CastellanoDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Ivan De KouchkovskyDivision of Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Vadim S KoshkinDivision of Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Joseph J ParkDivision of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
Ajjai AlvaDivision of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
Mehmet A BilenWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Tyler F StewartDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Rana R McKayDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Victor S SantosDivision of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT, USA.
Neeraj AgarwalDivision of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT, USA.
Jayanshu JainDepartment of Medicine, University of Iowa, Iowa City, IA, USA.
Yousef ZakhariaDivision of Oncology, Department of Medicine, University of Iowa, Iowa City, IA, USA.
Rafael Morales-BarreraVall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Michael E DevittDivision of Hematology/Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Michael GrantDepartment of Surgery and Cancer, Imperial College London, London, UK.
Mark P LythgoeDepartment of Surgery and Cancer, Imperial College London, London, UK.
David J PinatoDepartment of Surgery and Cancer, Imperial College London, London, UK.
Ariel NelsonDivision of Medical Oncology, Seidman Cancer Center at Case Comprehensive Cancer Center, Cleveland, OH, USA.
Christopher J HoimesDivision of Medical Oncology, Seidman Cancer Center at Case Comprehensive Cancer Center, Cleveland, OH, USA.
Evan ShreckDepartments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY, USA.ORCID 0000-0003-4388-6617
Benjamin A GartrellDepartments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY, USA.
Alex SankinDepartments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY, USA.
Abhishek TripathiStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Roubini ZakopoulouDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Aristotelis Bamias2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Jure MurgicDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.
Ana FröbeDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.
Alejo Rodriguez-VidaMedical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain.
Alexandra DrakakiDivision of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Sandy LiuDivision of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Vivek KumarDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Giuseppe Di LorenzoOncology University of Molise and ASL, Salerno, Italy.
Monika JoshiDivision of Hematology/Oncology, Department of Medicine, Penn State Cancer Institute, Hershey, PA, USA.
Pedro Isaacsson-VelhoDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Lucia Alonso BuznegoHospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain.
Ignacio DuranHospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain.
Marcus MosesDeming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA, USA.
Pedro BarataDeming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA, USA.
Guru SonpavdeGenitourinary Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Evan Y YuDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Jonathan L WrightDepartment of Urology, University of Washington, Seattle, WA, USA.
Petros GrivasDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Ali Raza KhakiDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0002-4655-4426
University of Washington Medical Center · USImperial College London · GBMontefiore Medical Center · USHospital Universitario 12 De Octubre · ESInstituto de Investigación Marqués de Valdecilla · ESNational and Kapodistrian University of Athens · GRSisters of Charity Hospital · HRTulane University · USUniversity of California, Los Angeles · USUniversity of California San Diego · USUniversity of California, San Francisco · USUniversity of Iowa · USUniversity of Michigan · USUniversity of Utah · USBrigham and Women's Hospital · USEmory University · USHarvard University · USHospital Del Mar · ESHospital Moinhos de Vento · BRMedical College of Wisconsin · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2M
NCATS NIH HHS UL1 TR002319NCI NIH HHS P30 CA023100NCI NIH HHS T32 CA009515Wellcome Trust
6 · The paper itself

Abstract

objectivesTo compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to developing metastatic disease. PATIENTS AND

methodsWe performed a retrospective cohort study collecting clinicopathological, treatment and outcomes data for patients with aUC receiving ICIs across 25 institutions. We compared outcomes (observed response rate [ORR], progression-free survival [PFS], overall survival [OS]) between patients with vs without prior RS, and by type of prior locoregional treatment (RS vs RT vs no locoregional treatment). Patients with de novo advanced disease were excluded. Analysis was stratified by treatment line (first-line and second-line or greater [second-plus line]). Logistic regression was used to compare ORR, while Kaplan-Meier analysis and Cox regression were used for PFS and OS. Multivariable models were adjusted for known prognostic factors.

resultsWe included 562 patients (first-line: 342 and second-plus line: 220). There was no difference in outcomes based on prior locoregional treatment among those treated with first-line ICIs. In the second-plus-line setting, prior RS was associated with higher ORR (adjusted odds ratio 2.61, 95% confidence interval [CI]1.19-5.74]), longer OS (adjusted hazard ratio [aHR] 0.61, 95% CI 0.42-0.88) and PFS (aHR 0.63, 95% CI 0.45-0.89) vs no prior RS. This association remained significant when type of prior locoregional treatment (RS and RT) was modelled separately.

conclusionPrior RS before developing advanced disease was associated with better outcomes in patients with aUC treated with ICIs in the second-plus-line but not in the first-line setting. While further validation is needed, our findings could have implications for prognostic estimates in clinical discussions and benchmarking for clinical trials. Limitations include the study's retrospective nature, lack of randomization, and possible selection and confounding biases.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsB7-H1 AntigenHumansImmune Checkpoint InhibitorsRetrospective StudiesB7-H1 AntigenCD274 protein, humanImmune Checkpoint Inhibitorsbladder cancer#BladderCancer#blcsmimmune checkpoint inhibitorsimmunotherapyoutcomesurinary tract neoplasms#urooncurothelial carcinoma#utuc

Identifiers

PMID34597472
PMCPMC10257152
OpenAlexW3203689165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.